.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,380,161

« Back to Dashboard

Details for Patent: 6,380,161

Title: Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
Abstract:The present invention provides methods and compositions for treating cancer and chemotherapy-resistant cancers comprising a chemotherapeutic agent conjugated to or coadministered with a peptide.
Inventor(s): Williams; Taffy (Lansdale, PA), Tuszynski; George (Pittsgrove, NJ), Actor; Paul (Phoenixville, PA)
Assignee: Inkine Pharmaceutical Company, Inc. (Blue Bell, PA) Philadelphia Health and Education Corporation (Philadelphia, PA)
Filing Date:Jun 20, 2000
Application Number:09/597,766
Claims:1. A method of treating a patient suffering from cancer, wherein a cancer chemotherapy agent is selected, conjugated to a peptide, and at least one dose is administered to the patient in a therapeutically effective amount, and wherein the peptide binds to a receptor for thrombospondin.

2. The method of claim 1, wherein the method is used to treat a patient with drug resistant cancer.

3. The method of claim 1, wherein the method is used to treat a patient with cancer, wherein the cancer is not a drug resistant cancer.

4. The method of claim 1, wherein the chemotherapy agent is selected from the group consisting of doxorubicin and paclitaxel.

5. The method of claim 1, wherein the peptide targets the chemotherapy agent to the cancer to be treated.

6. The method of claim 1, wherein the peptide binds to a receptor for thrombospondin.

7. A method of treating a patient suffering from cancer, wherein a cancer chemotherapy agent is selected, a peptide is selected, and at least one dose of the agent and peptide are coadministered to the patient in a therapeutically effective amount, wherein the peptide binds to a receptor for thrombospondin.

8. The method of claim 7, wherein the chemotherapy agent is selected from the group consisting of doxorubicin and paclitaxel.

9. The method of claim 7, wherein the peptide targets the chemotherapy agent to the cancer to be treated.

10. The composition of claim 7, wherein the peptide is Ala-Ser-Val-Thr-Ala-Arg (SEQ ID NO: 2).

11. A composition for treating a patient suffering from cancer, wherein the composition comprises a chemotherapy agent and a peptide, wherein the peptide is not Arg-Gly-Asp or Asn-Gly-Asp.

12. The composition of claim 11, wherein the composition is used to treat a patient with drug resistant cancer.

13. The composition of claim 11, wherein the chemotherapy agent is conjugated to the peptide.

14. The composition of claim 13, wherein the peptide is Cys(Acm)-Ser-Val-Thr- Cys(Acm)-Gly (SEQ ID NO: 6).

15. The composition of claim 13, wherein the peptide is Ala-Ser-Val-Thr-Ala-Arg (SEQ ID NO: 2).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc